GLMD: Galmed Pharmaceuticals Ltd Price-to-Revenue Multiple

Corporate company logo of Galmed Pharma (GLMD)

Galmed Pharmaceuticals (GLMD) capitalizes on its years of development and patents through licensing agreements with global corporations. The capitalization-to-revenue ratio exhibits volatility driven by the Middle East conflict's impact on business and anticipation of the Aramchol trial results. The current value of shows the level of this metric, capturing the market's real-time assessment of the company's ability to monetize its innovations amid inflationary pressures.

Price-to-Revenue Ratio: Galmed Pharmaceuticals Ltd. (GLMD) for 07/04/2022 - 11/14/2026

Analytical breakdowns for Galmed Pharmaceuticals (GLMD)

- share price and consensus valuation forecast:
Price Performance Chart galmedpharma.com|GLMD - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Galmed Pharma|GLMD - Enterprise Value
- book capitalization data:
Book Value per Share Galmed Pharmaceuticals|GLMD - Company Book Value|Market Value to Book Value Ratio galmedpharma.com|GLMD - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Galmed Pharmaceuticals|GLMD - Long-Term Debt to Capital|Current Liabilities to Capital galmedpharma.com|GLMD - Company Aggregate Debts|Debt to Book Value Ratio Galmed Pharma|GLMD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Galmed Pharmaceuticals|Critical Liquidity Ratio galmedpharma.com
- company profitability and valuation multiples indicators:
GLMD - Net Profit|Expected Net Income Galmed Pharmaceuticals|GLMD - P/E Multiple|Forward P/E Multiple galmedpharma.com|GLMD - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Galmed Pharma|GLMD - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Galmed Pharmaceuticals|GLMD - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth galmedpharma.com|GLMD - Earnings growth in current year|Expected earnings per share growth for next year Galmed Pharmaceuticals
- total revenue and sales volume data:
GLMD - Revenue and Sales Volume|Company Expected Sales Volume galmedpharma.com|GLMD - Market Cap to Revenue|Forward P/S Multiple Galmed Pharma
General company analysis:Galmed Pharmaceuticals Ltd (GLMD)
Original product of Galmed Pharma

The P/S ratio compares market capitalization to annual sales volume, allowing for an assessment of business value relative to its ability to generate revenue. For Galmed Pharmaceuticals (GLMD), whose commercial activity is temporarily limited while awaiting clinical trial results, changes in the P/S multiple serve as an indicator of speculative market expectations amid stagnating operating income.

Who Galmed Pharmaceuticals competes with

ARWR (arrowheadpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple MIRM (Mirum)|Price-to-Revenue Multiple Dynavax Corp|Arbutus - P/S Multiple|IVA - P/S Multiple|Gyre Therapeutics, Inc. (GYRE) - Price-to-Revenue Ratio|ASMB (assemblybio.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Galectin Therapeutics, Inc.|Market Cap to Revenue Genfit Corp (GNFT)|P/S Multiple DRRX|ALGS - Price to Sales|P/S Multiple BIVI (BioVie)|NDRA: Market Cap to Revenue Ratio|HEPA: Market Cap to Revenue